98 related articles for article (PubMed ID: 26832773)
21. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
22. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Simeone P; Alberti S
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27418631
[No Abstract] [Full Text] [Related]
23. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
[TBL] [Abstract][Full Text] [Related]
24. Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies.
Li D; Gao M; Li X; Xing M
J Cell Biochem; 2016 Jul; 117(7):1491-6. PubMed ID: 26841328
[TBL] [Abstract][Full Text] [Related]
25. Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage.
Finkel A; Liba L; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
J Clin Endocrinol Metab; 2016 Apr; 101(4):1407-13. PubMed ID: 26835544
[TBL] [Abstract][Full Text] [Related]
26. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
27. A Germline
Zhao Y; Yu T; Chen L; Xie D; Wang F; Fu L; Cheng C; Li Y; Zhu X; Miao G
Thyroid; 2020 Jun; 30(6):924-930. PubMed ID: 32041497
[TBL] [Abstract][Full Text] [Related]
28. Germline Mutations in Familial Papillary Thyroid Cancer.
Sarquis M; Moraes DC; Bastos-Rodrigues L; Azevedo PG; Ramos AV; Reis FV; Dande PV; Paim I; Friedman E; De Marco L
Endocr Pathol; 2020 Mar; 31(1):14-20. PubMed ID: 32034658
[TBL] [Abstract][Full Text] [Related]
29. Identification of a Novel Germline
Hu Y; Han Z; Guo H; Zhang N; Shen N; Jiang Y; Huang T
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275415
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.
Sánchez-Ares M; Cameselle-García S; Abdulkader-Nallib I; Rodríguez-Carnero G; Beiras-Sarasquete C; Puñal-Rodríguez JA; Cameselle-Teijeiro JM
Front Endocrinol (Lausanne); 2022; 13():829103. PubMed ID: 35295987
[TBL] [Abstract][Full Text] [Related]
31. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Biological Significance of DNA Methylation-Driven Differentially Expressed Genes in Biochemical Recurrence After Radical Prostatectomy.
Luo C; He S; Zhang H; He S; Qi H; Wei A
Front Genet; 2022; 13():727307. PubMed ID: 35186021
[No Abstract] [Full Text] [Related]
33. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
34. Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.
Cameselle-Teijeiro JM; Mete O; Asa SL; LiVolsi V
Endocr Pathol; 2021 Mar; 32(1):77-101. PubMed ID: 33495912
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic value of HABP2 as a novel biomarker for endometrial cancer.
Jiang Y; Li J; Sang C; Cao G; Wang S
Ann Transl Med; 2020 Sep; 8(18):1164. PubMed ID: 33241013
[TBL] [Abstract][Full Text] [Related]
37. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
38. Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.
Boufraqech M; Nilubol N
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31835496
[TBL] [Abstract][Full Text] [Related]
39. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
40. Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.
Shen CT; Zhang GQ; Qiu ZL; Song HJ; Sun ZK; Luo QY
Endocrine; 2019 Jun; 64(3):622-631. PubMed ID: 30826992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
